What did Pacific Edge Limited announce?
Pacific Edge Limited (NZX: PEB) filed “Bell Potter Healthcare Conference 2026” with NZX on 16 November 2026, as an operational update announcement.
From the announcement:“New Zealand – Pacific Edge (NZX/ASX: PEB) today releases a presentation it is giving to the Bell Potter Healthcare Conference commencing today.”
- Which company?
- Pacific Edge Limited (NZX: PEB)
- When was it filed?
- 16 November 2026
- Where is the original?
- NZX announcement
Bell Potter Healthcare Conference 2026
17 November 2026
BELL POTTER CONFERENCE PRESENTATION
DUNEDIN, New Zealand – Pacific Edge (NZX/ASX: PEB) today releases a presentation it is giving
to the Bell Potter Healthcare Conference commencing today.
The presentation is also available on Pacific Edge’s investor website (HERE)
ENDS
For more information:
Investors: Media:
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: +64 21 645 643
P: +64 22 032 1263
OVERVIEW
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way
in the development and commercialization of bladder cancer diagnostic and prognostic tests
for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in
Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its
wholly owned, and CLIA certified, laboratories in New Zealand and the USA.
Cxbladder: www.cxbladder.com
Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of
urothelial cancer in patients presenting with hematuria and those being monitored for recurrent
disease. The tests help improve the overall patient experience, while prioritizing time and
clinical resources to optimize practice workflow and improve efficiency.
Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than
twenty-five peer reviewed publications, and Cxbladder Triage is now included in the American
Urological Association’s Microhematuria Guideline. To drive increased adoption and improved
patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies
designed to generate further clinical utility evidence.
Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and
South America. In the US, the test has been used by over 5,000 urologists who have ordered
more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the
population via public healthcare and all residents have the option of buying the test online.
---
Bell Potter Healthcare Conference
Dr Peter Meintjes
Chief Executive Officer
November 17, 2026
1
DR PETER MEINTJES
Chief Executive Officer
PRESENTING TODAY
2
This presentation has been prepared by Pacific Edge Limited (PEL) solely
to provide interested parties with further information about PEL and its
activities at the date of this presentation).
A reference in this Important Notice and Disclaimer to the Information
means the information in this presentation and any verbal remarks made
by PEL directors or management(including answers to questions) in
respect of the matters addressed in this presentation.
Unless otherwise specified, the Information is stated at the date of this
presentation.The Information should be read in conjunction with PEL’s
Annual Report, half-year financial statements, and continuous disclosure
announcements released to NZX and ASX at
•www.nzx.com/companies/PEB; and
•https://www.asx.com.au/markets/company/PEB
Information of a general nature
The Information is of a general nature only and does not purport to be
complete or comprehensive. It does not contain all the information that
a person may require in evaluating or making an investment decision in
respect of PEL shares. Nor does it take into account any person’s
objectives or circumstances.
Not an offer
The Information is for informational purposes only. It is not an invitation
or offer of securities for subscription, purchase or sale for any purpose
or in any jurisdiction.
Not financial product advice
The Information does not constitute legal, financial, tax, investment, or
financial product advice, and is not a recommendation to invest in or
deal with PEL shares.
Past performance, including past PEL share price performance, cannot be
relied on as an indicator of future performance, including in respect of
PEL’s future financial performance, PEL’s future financial position, or
future PEL share price performance. Any investment in PEL shares is
subject to various risks, including those set out on pages 26 to 28 of
PEL’s Capital Raising Presentation that was released by NZX and ASX on
11 May 2026. If you are considering investing in or dealing with PEL
shares, you are encouraged to read those risks carefully, and to seek
your own professional advice, before you do so.
Forward-looking statements
The Information contains forward-looking statements that relate to
future events, outcomes or circumstances. Forward-looking statements,
by their very nature, are based on assumptions, estimates or
expectations about the future and involve inherent risks and
uncertainties. Many of those assumptions, estimates, expectations, risks
and uncertainties are matters that are beyond PEL’s control. There is no
assurance that any forward-looking statement will be realized or
achieved. Actual results or circumstances could differ (potentially
materially) from those statements.
Non-GAAP financial information
The Information contains certain financial measures that are “non-GAAP
financial information” under the New Zealand Financial Markets
Authority Guidance Note on disclosing non-GAAP financial information
and “non-IFRS financial information” under the ASIC Regulatory Guide on
disclosing non-IFRS financial information (and potentially under other
regulatory guidelines or rules).
Such financial information and financial measures do not have
standardized meanings prescribed under NZ IFRS or IFRS and therefore,
may not be comparable to similarly titled measures presented by other
entities, and should not be construed as an alternative to other financial
measures determined in accordance with NZ IFRS, or IFRS).
Currency
All dollar values to in the Information are in New Zealand dollars unless
otherwise stated.
Effect of rounding
A number of figures, amounts, percentages, estimates, calculations of
value and fractions in the Information are subject to the effect of
rounding. Accordingly, the actual calculations may differ.
Disclaimer
PEL has sought to use reasonable care to prepare the Information.
However, PEL and its related bodies corporate and affiliates, and their
respective directors, officers, partners, employees, agents, associates
and advisers (each such person, a PEL Person) do not make or provide
any representation, warranty or assurance, express or implied, of any
nature in respect of the Information (including, without limitation, as to
the accuracy, reliability or completeness of any of the Information or as
to whether any forward-looking statement will be realized or achieved or
the likelihood of this occurring).
No PEL Person is required or under any obligation to update this
presentation and, except where required by law or applicable Listing
Rules, no PEL Person is required or under any obligation to update the
Information.
To the maximum extent permitted by law, each PEL Person disclaims,
and no PEL Person shall have any, liability of any nature (including,
without limitation, arising from any fault or negligence) arising from or
in connection with (1) any person’s reliance on or use of the Information;
(2) any errors in or omissions from the Information; or (3) any failure to
update or correct the Information.
IMPORTANT NOTICE AND DISCLAIMER
3
INTRODUCTION TO PACIFIC EDGE
4
BLADDER CANCER – A SIGNIFICANT GLOBAL HEALTHCARE CHALLENGE
THE STANDARD OF CARE – CYSTOSCOPY – IS HIGHLY INVASIVE, UNCOMFORTABLE AND COSTLY
5
1.Sievert et al (2009) Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009 Mar 7;27(3):295–300. doi: 10.1007/s00345-009-0395-z
2.World Cancer Research Fund. Statistics are from 2022. Growth due to aging population.
3.Average recurrence for low grade non-muscle invasive bladder cancer as published in Palou J et al (2012): Eur Urol 2012; 62: 118.
4.Source: Nursing Skills
5.Guldhammer et al (2024), “Cystoscopy Accuracy in Detecting Bladder Tumors: A Prospective Video-Confirmed Study.” Cancers. 2024;16(1):160. DOI: 10.3390/cancers16010160
6.Cxbladder Triage Plus Test Report, 07-QMS-091-US Rev A: NPV for scores below 0.15.
7.American Urological Association (AUA) 2025 Microhematuria Guideline.
B L A D D E R C A N C E R : A C O S T L Y , R E C U R R I N G D I S E A S E
1
st
Costliest cancer to treat on a
per-patient basis
1
6
th
Most common cancer in men
2
>50%
Recurrence, driving years of
repeat surveillance
3
TODAY’S STANDARD OF CARE
Cystoscopy: a scope into the bladder
A camera on the end of a scope is inserted
up the urethra to visually inspect the lining
of the bladder wall
4
Why it falls short
•Invasive and uncomfortable – patients defer or drop out of surveillance
•Costly, and consumes scarce urologist capacity
•Low yield – most patients scoped do not have cancer
•Have high variability between urologists, and only 81% sensitivity
5
I M P R O V E D : N O N-I N V A S I V E S T A N D A R D O F C A R E
Cxbladder: just pee in a cup
A simple urine test that detects and rules out bladder cancer –
no invasive cystoscopy required
99.4%
6
NPV: a negative result confidently rules out
cancer
Grade A Rating
7
AUA evidence rating in the 2025
Microhematuria Guideline
Why it solves the problem
•Collected at clinic or at home – no procedure, no discomfort
•Rules out cancer, reserving cystoscopy for those who need it
•Lower cost for payers and frees urologist capacity
ONE URINE SAMPLE, A CLEAR ANSWER AT EVERY STAGE OF CARE
CXBLADDER RULES OUT CANCER OR PRIORITIZES PATIENTS FOR CYSTOSCOPY
Symptoms
Hematuria (blood in urine)
The primary symptom of bladder
cancer, ~7m US patients a year
Disease management
Cxbladder Triage Plus testing
Rule out cancer or prioritize patients
for cystoscopy
Surgical intervention
TURBT – surgical resection
Tumor resected via cystoscope;
pathology confirms stage and grade
Surveillance
Cxbladder Monitor · Surveillance Plus
Monitor NMIBC patients for recurrence
1
Collect
Pee in a cup, at clinic or home
2
Analyze
Pacific Edge labs
Dunedin, NZ · Hershey, PA
RNA + DNA biomarkers, one
sample, Pacific Edge labs
3
Report
4
Interpret
LOW <0.15
De-intensify patient work-up
84.1% of patients; 0.6% risk of UC
INTERMEDIATE 0.15–0.54
Further clinical evaluation
9.5% of patients; 27.7% risk of UC
HIGH ≥0.54
Prioritize for cystoscopy
6.4% of patients; 74.6% risk of UC
THE PATIENT JOURNEY
THE PATIENT EXPERIENCE
Cxbladder Triage Plus
T E S T R E P O R T
0.05
LOW PROBABILITY
of urothelial carcinoma: 0.6%
95% CI (0.02 – 0.10)
LOW 0.6%27.7%74.6%
0.000.150.541.00
Sample result shown on the current Cxbladder Triage Plus report format. Not patient data.
TURBT: transurethral resection of a bladder tumor. NMIBC: non-muscle invasive bladder cancer. UC: Urothelial Carcinoma
6
DRIVING ECONOMIC VALUE FOR PATIENTS, CLINICIANS, HOSPITALS AND PAYERS
CXBLADDER DELIVERS CLINICAL UTILITY, PATIENT SATISFACTION, IMPROVED ACCESS AND ECONOMIC VALUE
TODAY: 100 microhematuria patients, all receive a cystoscopy
WITH CXBLADDER TRIAGE PLUS: 85 avoid cystoscopy
1
No cystoscopy, no cancerCystoscopy, no cancerCystoscopy, cancer
15% receive cystoscopy to find the same 5 cancer patients. Illustration assumes bladder cancer
incidence in microhematuria populations of 5%
2
85%
of cystoscopies safely
avoided
62%
of US counties don'thave
a registered urologist
4
13%
of high-risk patients
receive a cystoscopy
5
Patients
Low risk avoid an invasive, uncomfortable procedures,
high risk are prioritized for diagnostic cystoscopy
Clinicians
Confident rule-out (99.4% NPV) focuses cystoscopy on
patients most likely to have cancer
Hospitals
Urologists per person over 65 are falling
6
, potentially
delaying diagnosis. Cxbladder frees scarce capacity
Payers
Save >US$500 per patient
3
, as Medicare reimbursement
for cystoscopy declines
7
One urine test: better access, capacity and economics
1.Illustrative application of the observed risk distribution. Actual outcomes will vary, and no diagnostic test identifies every cancer
2.AUA Guidelines cite incidence of bladder cancer in microhematuria risk categories from 0.4-6%. 5% is an example
3.Tyson et al (2024) Budgetary Impact of Including the Urinary Genomic Marker Cxbladder Detect in the Evaluation of Microhematuria Patients - PubMed (PMID: 37914255)
4.https://www.auanet.org/research-and-data/aua-census/census-results
5.https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.25048
6.Nam et al. (2021) Projected US Urology Workforce per Capita, 2020-2060 JAMA Network Open Published Online: November 16, 2021
7.https://www.cms.gov/medicare/physician-fee-schedule/search
7
US$10.6b
Global TAM
1
CXBLADDER MARKET OPPORTUNITY
CXBLADDER OFFERS A SIGNIFICANT ADDRESSABLE GLOBAL MARKET ANNUALLY
~17m0.47m | 2.71m | 3.46m1.7m ~58k ~300k US$2.0b830m
~12m0.34m | 1.96m | 2.5m1.7m ~180k ~1mUS$1.9b600m
APAC
Primary growth
focus due to higher
CMS pricing
NZ market mature.
Australia and SEA in
business development
New market accessed
via IVD / kitted tests
1.Pacific Edge estimate combining US, APAC and Europe. See slides 31-33 for assumptions regarding eligible populations, testing frequency and pricing.
2.RDM: Residual Disease Monitoring
3.TRM: Therapeutic Response Monitoring
4.Management estimates derived from referred hematuria data in Woldu et al (2021), so do not add to ~7m figure for total incidence. See slides 36-38 for details.
All
hematuria
Microhematuria
4
Low | Intermediate | High
Gross
4
Hematuria
Annual cases of
bladder cancer
Living with bladder cancerTAMPopulation
SURVEILLANCE
(RDM
2
, TRM
3
, RECURRENCE)
PATIENT/DISEASE MANAGEMENT
(CLINICAL DECISION MAKING)
8
~7m0.20m | 1.14m | 1.46m0.7m ~90k ~750k US$6.7b340m
STRATEGY AND PROGRESS
9
10
MEDICARE: FINAL LCD COVERS TRIAGE AND TRIAGE PLUS
ACCESS TO ~71M LIVES SUBJECT TO LCD ELIGIBILITY CRITERIA
FINAL LCD (L40378): PUBLISHED 4 NOV 2026 | EFFECTIVE 20 DEC 2026
•Sole coverage: only Cxbladder Triage and Triage Plus are covered for intermediate-risk
microhematuria (~1.14m patients/year)
1
; competing tests and generic codes are non-covered
•Removes adoption barriers: eliminates reimbursement and logistical objections from
ordering clinicians
•Higher ASP
2
: Triage US$1,057 and Triage Plus US$1,328 per test, supporting revenue growth,
operating leverage and cashflow
•Medicare Advantage: expected to reimburse in line with Medicare policy, boosting cashflow
•Commercial payers: Medicare coverage can be leveraged to drive policy adoption and
appeals
~71M
Medicare lives
~2.8M
Microhematuria
opportunities / yr
1
US$1,328
Triage Plus price per test
“Cxbladder Triage has the most published evidence specific to
MH evaluation and is referenced in the AUA/SUFU 2025 guideline
as one option that may be considered for appropriately
counseled intermediate-risk patients...”
Novitas L40378, ‘Urine-based Biomarkers in Patients with
Microhematuria’
PATH FORWARD: EVIDENCE TO EXPAND COVERED INDICATIONS AT NEXT UPDATED LITERTURE REVIEW BY AUA
Q4 2026Q1 2027Q2 2027Q3 2027Q4 20272025
DRIVE - CV of Triage Plus
AUSSIE - CV of Triage Plus
microDRIVE - CV of Triage Plus
Pooled Analysis MH & GH - CV of Triage Plus
STRATA second publication - CU of Triage
AUA updated literature review - Expected window
Published Oct 2026
Published Nov 2025
1.Management estimate, see Slide 8.
2.Legacy tests had a Medicare approved price of US$760
CU = clinical utility; CV = clinical validity; MH = microhematuria; GH = gross hematuria
US PAYER CONVERSION: FROM POLICY TO CONTRACT
EFFECTIVE MEDICARE COVERAGE FROM 20 DECEMBER 2026 EXPECTED TO UNLOCK COMMERCIAL VOLUMES
11
1.Medicare, Blue Cross Blue Shield (BCBS) North and South Carolina and Kansas City Missouri, Hawaii Medical Services Association (Hawaii BCBS),Southern
California Permanente Medical Group (Kaiser SoCal), Sentara, Geisinger and MVP Healthcare
2.BCBS NC and SC, Kaiser SoCal and Medicare
3.Kaiser SoCal and Highmark
4.Kaiser SoCal
5.The figures represented are from Policy Reporter and are likely to be an underestimate of lives under policy and in-network due to some Insurers and their
subsidiaries administering government and other third-party programmes, not included in Policy Reporter.
US COMMERCIAL MARKET
MEDICARE AND FAVOURABLE MEDICAL
POLICY
MEDICARE AND IN-NETWORK CONTRACTS
SECURED
81.3m
Policy lives
1&5
78.6m
Contracted lives
2,5
4.9m
Contracted lives
4,5
223m
US private insured lives
Source: US Census
1,200
US private health insurance payers
Source: NAIC
71m
Medicare insured lives
Source: CMS
9.18m
VA covered lives
Source: VA
8.4m
Policy lives
3,5
CONVERTING POLICY AND CONTRACTING INTO REVENUE
INTEGRATED DELIVERY NETWORKS ARE OUR PRIORITY
12
1.Management estimates derived from referred hematuria data in Woldu et al (2021). See slides 36-38 for details.
2.Share of patient volume figures are management estimates
51%
30%
8%
7%
4%
Hospital Networks
Academic Centers
Veterans
Administration
Kaiser Permanente
Other
1.68m
INTEGRATED DELIVERY NETWORKSPRIVATE PRACTICE
2.8m
1
80%
20%
Large Urology
Group Practices
Community
Urology
1.12m
Low risk
80%20%
Intermediate risk
75%25%
High risk
34%66%
FemaleMale
60% of patient volume40% of patient volume
US SERVICEABLE MARKET
Medicare coverage is for
1.14m Intermediate Risk
PROVIDER MIX WITHIN CHANNEL
2
PROVIDER MIX WITHIN CHANNEL
2
AUA RISK CATEGORY BY SEX (AT BIRTH)
1.Net cash, cash equivalents and short-term deposits at the end of the period
2.Provisional CMS prices released Q2 27 expected to become final and effective 1 Jan 2027
3.Management Estimates
4.Profitability threshold determined on an annualized basis across all products with a blended ASP >$NZD 1,450. Actual breakeven will vary with payer mix, collection rates, product mix and operating investment
13
Financial Period (NZ$M)
2H 26
(Unaudited)
1H 26
(Unaudited)
FY 26
(Audited)
2H 26 vs
1H 26
Operating Revenue$5.6$5.9$11.5(6.4%)
Total Revenue$6.5$7.1$13.6(9.3%)
Operating Expenses$23.1$26.2$49.4(11.9%)
Net Loss After Tax($16.7)($19.1)($35.8)(12.8%)
Net Cash Flows to Operating
Activities
($12.9)($19.0)($31.9)(32.1%)
Net Cash
1
$7.8$22.1$7.8(64.8%)
Monthly Cash Burn $2.4$3.3$2.9(27.7%)
Key milestones on our path to profitability:
NZ$36.1m raised
Raise completed in June 2026
Cash Burn <$2.5m/month
2H26 burn of NZ$2.4m/month, cash preservation
measures continued
20 December 26
Final LCD
Jan 2028
3
Surveillance Plus claims
(targeted)
~55,000 tests/yr
4
Profitability breakeven
FINANCIALS AND PATH TO PROFITABILITY
COST DISCIPLINE PRESERVES THE UPSIDE AS MEDICARE COVERAGE APPROACHES
US pricing increases from 1 Jan 2027
Triage Plus US$1,328; Triage US$1,057
2
(↑39%)
Monitor US$1,026
2
(↑35%)
14
PACIFIC EDGE CATALYSTS FOR LONG-TERM SUSTAINABLE GROWTH
1
AN EXPANDING SERVICEABLE MARKET AND REVENUE
1
Medicare coverage
high-risk Microhematuria
2
Surveillance Plus
launched
3
Medicare coverage
Gross Hematuria patients
4
Kitted RUO
2
launch
5
Kitted IVD
3
launch
6
New product
launch
N E A R-T E R MM E D I U M-T E R ML O N G E R-T E R M
1.Illustrative only. The curves indicate the sequence and relative scale of expected market expansion, not forecast revenue
2.RUO is for “research use only” and limits the clinical claims that can be made and the payment options
3.IVD is an in vitro diagnostic and subject to country-specific product registrations, regulations and reimbursement processes
4.Profitability threshold determined on an annualizedbasis across all products with a blended ASP >$NZD 1,450. Actual breakeven will vary with payer mix, collection
rates, product mix and operating investment
PE GROUP profitability at
~55,000 tests/year
4
C U M U L A T I V E R E V E N U E
OUTLOOK: POSITIONED TO UNLOCK VALUE
FIRST MOVER; LARGE MARKET; BACKED BY EVIDENCE; KEY COMMERCIAL CATALYSTS
1st
First mover &
market leader
Urine-based, non-invasive
bladder cancer tests
US$10.6b
1
Global market
opportunity
Driven by ~7m US hematuria
patients a year
Grade A
AUA
2
evidence rating
Cxbladder Triage: the only
urine biomarker rated
‘Grade A’
Medicare LCD
Triage and Triage Plus - the only
tests covered by CMS in L40378
Coverage effective from 20
December 2026 for 71 million
US lives
Pricing
Improving sales force
unit economics
Triage Plus US$1,328; Triage
US$1,057; Monitor US$1,026
vs. US$760
3
on legacy
products
1.US$10.6b is a Pacific Edge estimate; see appendix for assumptions.
2.AUA: American Urological Association.
3.New Triage and Monitor prices provisional and subject to finalization; expected effective on 1 Jan 2027
15
Global commercial traction
Commercial payer and Medicare policy wins bring 78.6 million US lives under contract for hematuria evaluation;
volume growth and favorable prices drive APAC towards profitability on a direct cost basis
APPENDIX
16
PACIFIC EDGE IS FOUNDED ON DELIVERING POSITIVE OUTCOMES FOR SOCIETY
WE CREATE VALUE BY PRIORITISING OUR PATIENTS, OUR PHYSICIANS AND OUR PEOPLE
WE PUT PATIENTS FIRST IN EVERYTHING WE DO
•WE are committed to customer success
•WE are guided by data and evidence
•WE are trusting and transparent
•WE support our teammates
•WE celebrate successes, large and small
17
Our Mission
To help improve people’s lives and patient
outcomes by providing leading solutions for the
early detection and management of cancer
Our Vision
A world where the early diagnosis and better
treatment of cancer is within reach of everyone
PACIFIC EDGE – THE FIRST MOVER AND LEADER IN BLADDER CANCER DIAGNOSTICS
A GLOBAL COMPANY WITH A GLOBAL OPPORTUNITY
18
1.See slides 31 - 33 for assumptions
US$10.6b
1
Global Market Opportunity
Jan 2026
Kaiser RWE published
supporting Triage.
Largest ever UBB
1
hematuria study
May 2026
Novitas publishes
Draft LCD DL40378
with coverage for
Triage Plus and
Triage
Nov 2026
Novitas Final LCD;
effective 20 Dec 2026
Dec 2014
Launch of
Cxbladder
Triage
Nov 2023
Kaiser EMR
integration
goes live
Dec 2022
Lotan et al:
Enhanced
Cxbladder
Tests Deliver
Improved
Performance.
Journal of
Urology
Feb 2018
Cxb Triage
adopted into
Canterbury
Community Health
Pathways with
primary care
referral
2011
2011
Pacific Edge
Diagnostics
New Zealand
(PEDNZ)
established
2012
Dec 2012
Launch of Pacific Edge
Diagnostics USAand
Cxb Detect
2013
Mar 2013
First commercial
sale (Cxb Detect)
for PEDUSA
May 2013
First commercial
sale (Cxb Detect)
for PEDNZ
2014
2015
Dec 2015
Launch of
Cxbladder
Monitor
2016
2018
2019
2020
Jun 2020
Kaiser Permanente,
approves commercial
use of Cxbladder
Jul 2020
Medicare
reimbursement of
Cxbladderat
US$760/test
2021
Aug 2021
Cxbladder reaches
70% public
healthcare
coverage in NZ
2022
2023
2024
May 2024
STRATA podium
presentation at
AUA 2024.
Study published
in Journal of
Urology
TIMELINE: COMPANY MILESTONES
2025
Feb 2025
Triage included in AUA
Microhematuria
Guideline
Apr 2025
Medicare non-
coverage
effective
Nov 2025
Triage Plus gets CMS
draft price of
US$1,328
2026
1.UBBs are urine-based biomarkers – a term adopted by AUA in their guidelines
THE CXBLADDER SUITE: TRIAGE AND TRIAGE PLUS FOR HEMATURIA EVALUATION
TESTS TO RULE OUT BLADDER CANCER AND IDENTIFY THOSE MOST NEEDING SPECIALIST CARE
HEMATURIA EVALUATION
NEGATIVE RESULT
RULE OUT BLADDER CANCER
The test combines a High Negative Predictive Value with
High Sensitivity (it picks up most cancers)
POSITIVE RESULT
PRIORITIZE SPECIALIST CARE
The test combines a High Positive Predictive Value with
High Specificity (it delivers few false positives)
PERFORMANCEKavalieris et al. (2015)
1
•Sensitivity: 95%
•Specificity: 45%
•Negative Predictive Value: 99%
•Positive Predictive Value: N/A
Harvey et al. (2025)
2
•Sensitivity: 93.6%
*
•Specificity: 98.2%
**
•Negative Predictive Value: 99.4%
*
•Positive Predictive Value: 74.6%
**
WHEN IT IS USED: Prior to cystoscopy
Prior to cystoscopy / as an adjunct /
3 weeks post cystoscopy
COMMERCIALLY AVAILABLEGlobally availableGlobally available
AUA GUIDELINEGrade A EvidenceAssessment expected in 2027
MEDICAREUS$1,058
3
(Effective 20 December 2026)US$1,328 (Effective 20 December 2026)
20
1.Kavalieris et al. (2015) A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma. BMC Urol 2015;15:23.
2.Harvey et al. (2025) Analytical Validation of the Cxbladder® Triage Plus Assay for Risk Stratification of Hematuria Patients for Urothelial Carcinoma. Diagnostics. 2025; 15(14):1739. https://doi.org/10.3390/diagnostics15141739
3.Provisional CMS prices released Q2 27 expected to become final and effective 1 Jan 2027
* When lower 0.15 cut point on test report is used
** When higher 0.54 cut point on test report is used
THE CXBLADDER SUITE: MONITOR AND SURVEILLANCE PLUS
ALTERNATIVE TO CYSTOSCOPY FOR NMIBC
1
PATIENTS UNDERGOING SURVEILLANCE FOR RECURRENCE
NMIBC
1
CANCER SURVEILLANCE RECURRENCE
NEGATIVE RESULT
RULE OUT BLADDER CANCER RECURRENCE
The test combines a High Negative Predictive Value
with High Sensitivity (it picks up most cancers)
•In development, showing improved
performance
PERFORMANCE
•Sensitivity: 93%
2,3
•Specificity: N/A
•Negative Predictive Value: 97%
2,3
•Positive Predictive Value: N/A
•Sensitivity: not yet published
•Specificity: not yet published
•Negative Predicative Value: not yet
published
•Positive Predictive Value: not yet
published
WHEN IT IS USED:
At any surveillance time point 9 months
after the most recent cancer diagnosis
At any surveillance time point after the
first surveillance cystoscopy (6 weeks)
COMMERCIALLY AVAILABLE
Globally available•USA: CPT-PLA code targeted for Jun
2027, reimbursement from Jan 2028
•APAC: Soft launch from Q2 FY28
GUIDELINES
NCCN
4
2bNot yet available for assessment
MEDICARE
US$1,026
5
(non-covered)Seeking US$1,800
6
(not yet covered)
21
1.NMIBC: non-muscle invasive bladder cancer
2.Kavalieris et al. (2017) Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol 2017;197:6,1419-1426.
3.Lotan et al. (2017) Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations. Elsevier; 2017; 1–8.
4.NCCN: National Comprehensive Cancer Network
5.Provisional CMS prices released Q2 27 expected to become final and effective 1 Jan 2027
6.Seeking pricing by way of crosswalk
FY 26 FINANCIAL PERFORMANCE: POSITIONING FOR MEDICARE RE-COVERAGE
COST SAVINGS MINIMIZE CASH BURN; $36.1 MILLION CAPITAL RAISE IN MAY 2026 STRENGTHENS BALANCE SHEET
1.Net cash, cash equivalents and short-term deposits at the end of the period
22
Financial Period (NZ$M)
1H 26
(Unaudited)
2H 26
(Unaudited)
FY 26
(Audited)
FY 25
(Audited)
2H 26 vs 1H
26
FY 26 vs FY 25
Operating Revenue$5.9$5.6$11.5$21.8(6.4%)(47.4%)
Total Revenue$7.1$6.5$13.6$24.6(9.3%)(44.8%)
Operating Expenses$26.2$23.1$49.4$54.6(11.9%)(9.5%)
Net Loss After Tax($19.1)($16.7)($35.8)($30.0)(12.8%)19.5%
Cash Receipts from Customers$8.0$5.2$13.2$21.6(34.3%)(38.7%)
Net Cash Flows to Operating Activities($19.0)($12.9)($31.9)($24.7)(32.1%)29.1%
Net Cash
1
$22.1$7.8$7.8$22.6(64.8%)(65.5%)
Monthly Cash Burn $3.3$2.4$2.9$2.3(27.7%)23.4%
FINANCIAL PERFORMANCE OPERATING EXPENSES
ALL COSTS REDUCED WITH LARGEST REDUCTION IN SALES AND MARKETING
23
Financial Period (NZ$M)
1H 26
(Unaudited)
2H 26
(Unaudited)
FY 26
(Audited)
FY 25
(Audited)
2H 26 vs
1H 26
FY 26 vs
FY 25
Laboratory Operations $5.9$5.7$11.6$12.5(2.8%)(7.1%)
Research $7.1$6.4$13.4$14.6(9.9%)(8.2%)
Sales and Marketing $8.5$6.8$15.2$17.5(20.0%)(13.2%)
General Administration$4.8$4.3$9.1$9.9(11.8%)(8.1%)
Total operating expenses $26.2$23.1$49.4$54.6(11.9%)(9.5%)
PACIFIC EDGE’S EVIDENCE PROGRAM SEEKS TO CHANGE CLINICAL PRACTICE
Clinical Evidence
AV, CV, CU
HEALTHCARE PAYERS
(Medicare, Kaiser
Permanente, Veterans
Administration, private
payers, etc).
- Change Medical Policy
(practice)
- Change Reimbursement
Policy
PROFESSIONAL SOCIETIES
(AUA, EAU, NCCN)
- Change Standard of Care
Guidelines
Guidelines change:
- Healthcare Payer Medical
and Reimbursement
Policies
Guidelines change:
- Clinical Practice
UROLOGISTS - Change Clinical Practice
EVIDENCE DEVELOPED IN A STRUCTURED FRAMEWORK:
•Analytical Validity (AV): Evidence that a test is repeatable in the lab for a given indication and population
•Clinical Validity (CV): Evidence a test works in the same way on an independent eligible population for a given indication
•Clinical Utility (CU): Evidence that a test changes clinical practice in the hands of a physician; CU evidence obtained through randomized control trials can
provide a high level of support for guideline change (in addition to AV and CV evidence)
•Real World Evidence (RWE): CU verification of the real-world use of the test in clinical practice, usually through regular use of the test by physicians
AUDIENCE
EVIDENCE USE
24
Calendar year
Pre
2023
202320242025202620272028
Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2
STRATA
DRIVE
AUSSIE
microDRIVE
Pooled CV
CREDIBLE
HEMATURIA EVALUATION FIVE-YEAR CLINICAL STUDIES ROADMAP
*
*
*
*
*
Publication Submitted
Records review / follow-up
Database lock
Legend:
Pre-activation (docs, CTA etc)
SIV
Enrollment
Data Cleaning
*
DBL
DBL
DBL
25
Calendar year
Pre
2023
202320242025202620272028
Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2
“The 1800”
1
LOBSTER
OCTOPUS
*
SURVEILLANCE FIVE-YEAR CLINICAL STUDIES ROADMAP
26
Publication Submitted
Records review / follow-up
Database lock
Legend:
Business case approved
SIV
Enrollment
Data Cleaning
*
DBL
Scheduled surveillance visits
CAB
2
1.“The 1800” is the Surveillance Plus development dataset
2.CAB is the Pacific Edge Clinical Advisory Board. It was convened at SUO in Arizona to review and confirm the clinical study trial design for OCTOPUS
27
DRIVING CLINICAL VALUE FOR PHYSICIANS, HOSPITALS AND PAYERS
COMPELLING CLINICAL EVIDENCE CHANGES CLINICAL PRACTICE, MEDICAL POLICY AND GUIDELINES
Clinical Utility (CU) - Evidence a test that can usefully change patient management within the context of care for the defined population and indication Clinical Validity (CV) - Evidence a test works in
the same way on an independent eligible population for a given indication. Analytical validity (AV) - Evidence a test is repeatable in the lab for a given indication and population
STUDY
TEST AND EVIDENCE
PUBLICATION DATE
(1)
1. STRATA Clinical Utility
- CU of Triage
Published May 2024
2. Automated RNA & DNA extraction
- AV of Triage, Detect and Monitor
Published September 2024
3. Triage Plus Analytical Validation
- AV of Triage Plus
Published July 2025
4. DRIVE Clinical Validation
- CV of Triage Plus
Published October 2025
5. STRATA second publication
- CU of Triage
Q3 2027
6. AUSSIE Clinical Validation
- CVof Triage Plus
Published October 2026
7. microDRIVE Clinical Validation
- CV of Triage Plus
Q1 2027
8. Surveillance Plus Analytical Validation
- AV of Surveillance Plus
Q2 2027
9. Pooled Analysis MH & GH Clinical Validation
2
- CV of Triage Plus
Q3 2027
10. LOBSTER Clinical Validation
- CV of Monitor/Surveillance Plus
Q3 2027
11. CREDIBLE Clinical Utility
- CU of Triage Plus
Q1 2028
12. OCTOPUS Clinical Utility
- CU Surveillance Plus
No timeline at this point
1
All dates are calendar year and our best current estimates
2
The MH and GH pooled analysis brings together data from DRIVE, AUSSIE and microDRIVE
Already published evidence
Expected to be published before AUA microhematuria guideline committee initiates next literature review in Q3 2027
INDEPENDENT STUDIES SUPPLEMENT OUR EVIDENCE PORTFOLIO
HIGH IMPACT RESEARCH AT LOW COST
1.All dates are calendar year and our best current estimates. Timelines are controlled by the investigator
2.Filson et al (2026); Real-World Utility of Cxbladder Triage for Patients with Microhematuria: A Matched Cohort Study, Urology Practice® (2026), doi:
10.1097/UPJ.0000000000000972.
3.BCG: Bacillus Calmette–Guérin is a bacterium instilled into the bladder that triggers an immune response that targets and destroys cancer cells.
4.MIBC: Muscle Invasive Bladder Cancer
INDEPENDENT STUDY FOCUSINSTITUTIONTEST AND EVIDENCE TYPE
PUBLICATION
DATE
1
Real World Utility of Triage in MH: A Matched
Cohort Study
Kaiser Permanente, USCU Triage (RWE)Q1 2026
2
Patient preference and satisfaction of
“biomarkers vs cystoscopy”
Mayo Clinic, USCU MonitorQ4 2026
NZ Hematuria Pathway comparing T/D with
Triage Plus on AUSSIE samples
Canterbury DHBCU of Triage PlusQ1 2027
Retrospective comparison of Triage and Triage
Plus in the Kaiser System
Kaiser Permanente, USCU Triage Plus2027
Test utility in screening patients at risk for
bladder cancer
UT Southwestern, USCU Triage Plus 2027
Test utility in assessing therapy success in a
reduced chemotherapy protocol for upper tract
tumors
Israel Institute of
Technology, Israel
CU Monitor
CU Surveillance Plus
2027
Test utility in assessing response to BCG
3
in high-
grade bladder cancer patients
University of Miami, US
CU Monitor
CU Surveillance Plus
2027
Test utility for the surveillance of MIBC
4
treated
with bladder sparing methods (PRESERVE Trial)
Cleveland Clinic, US
CU Monitor
CU Surveillance Plus
2028
A Randomized Trial of Apalutamide in Non-
Muscle Invasive Bladder Cancer
National Institutes of
Health, US
CU Monitor
CU Surveillance Plus
2029
Already published evidence
28
•Investigator initiated trials (IITs) are
independent studies in which Pacific Edge
typically provides free testing, so provide
significant value at low cost
•IITs extend the evidence portfolio for new
indications of existing tests and may inform
new ‘core’ clinical trials
•IITs are an important part of Key Opinion
Leader (KOL) engagement and generate
publications or podium presentations that
give profile to Cxbladder and Pacific Edge
BACKGROUND ON NMIBC AND MIBC
•Bladder Cancer
•An estimated 83,190 patients were diagnosed with bladder cancer in the USA in 2024 at an average age of 73
1
•Non-muscle invasive Bladder Cancer (NMIBC)
•NMIBC tumors represent approximately 75% of the bladder cancer diagnoses each year (CIS, Ta and T1)
•NMIBC tumors are localized and present on the lining of the bladder wall and shed cancer cells and cell-free DNA/RNA into the urine in the bladder
•NMIBC tumors are highly treatable with surgery/resection and deemed cancer free after surgery/resection
•NMIBC patients are placed on a surveillance protocol after surgery/resection, because recurrence can be 50-70% within the first two years
2
•NMIBC → TURBT → Surveillance
•Muscle-invasive Bladder Cancer (MIBC)
•MIBC tumors represent approximately 25% of the bladder cancer diagnoses each year (T2-4)
•MIBC tumors differ from NMIBC tumors, because they shed cells/nucleotides to the blood
•MIBC patients have advanced/serious disease, require high-levels of intervention (radical cystectomy followed by multiple therapies)
•MIBC patients are not deemed cancer free after cystectomy and frequently monitored for residual and metastatic disease
•MIBC → Cystectomy → Monitoring
1.American Cancer Society. Cancer Facts & Figures 2024
2.Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of
non-muscle invasive bladder cancer: AUA/SUO guideline: 2024
amendment. J Urol. 2024;10.1097/JU.0000000000003846.
NMIBC STANDARD OF CARE: INTERVENTION AND SURVEILLANCE
•NMIBC Standard of Care – Intervention
•After NMIBC diagnosis, the standard intervention is a Trans-Urethral Resection of a Bladder Tumor (TURBT)
•TURBT involves inserting a camera into the urethra and the use of small instruments like a wire loop or laser to cut or burn away the tumor tissue
•Patients are deemed cancer free post TURBTwhen muscles and tumor margins are confirmed free of disease by pathology
•A resection biopsy taken during surgery is used to stage the tumor (T0, Ta, CIS, T1-4) and determine the grade (low or high grade) which also
provides the risk of recurrence.
•All NMIBC patients are then classified into risk categories based on this information (low, intermediate and high risk).
•NMIBC Standard of Care - Surveillance
•BCG (bacillus calmette guérin) is administered for several weeks after TURBT to initiate an immune response towards the tumor. Some
patients are ‘non-responders’
•A cystoscopy at 3 months is recommended for every patient
•Following the 3-month cystoscopy, patients are recommended for routine surveillance protocols involving cystoscopy and imaging among
others based on their risk category
•Due to the high burden of these protocols, the average patient only stays on surveillance for1.8 years not 5
1
as recommended by most
guidelines
1.AUA AQUA Registry
SOURCES AND ASSUMPTIONS - TOTAL ADDRESSABLE MARKET (US)
31
REGIONSTATISTICSOURCE
UNITED STATES
Population 341,762,685https://www.census.gov/popclock/
Incidence of hematuria7,000,000
Presentation from Dr Sia Daneshmand (Director of
Urologic Oncology and Clinical Research, USC) July 2019
Referred for clinical workup3,500,000
Presentation from Dr Sia Daneshmand (Director of
Urologic Oncology and Clinical Research, USC) July 2019
Proportion of gross hematuria amongst
those referred for clinical workup700,000Pacific Edge estimate
Proportion of microhematuria amongst
those referred for clinical workup2,800,000Pacific Edge estimate
Proportion of low-risk microhematuria 200,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Proportion of intermediate-risk
microhematuria 1,140,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Proportion of high-risk microhematuria 1,460,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Annual cases of bladder cancer 84,870
National Cancer Institute
Patients living with bladder cancer 744,044
National Cancer Institute
Test opportunities 4,616,066Pacific Edge estimate
Price of Cxbladder (US$)
$1,328 for Cxbladder Triage Plus, $1,800 for Cxbladder
Surveillance Plus
Surveillance Plus is a target price sought by crosswalk
and has not yet been established or covered
TAM (US$billion)$6.7
SOURCES AND ASSUMPTIONS - TOTAL ADDRESSABLE MARKET (EUROPE)
32
REGIONSTATISTICSOURCE
EUROPE (EXCLUDING
RUSSIA)
Population
600,000,000World-population - Europe
World-population - Russia
Incidence of hematuria12,000,000
Science Direct
Referred for clinical workup6,000,000
Presentation from Dr Sia Daneshmand (Director of
Urologic Oncology and Clinical Research, USC) July 2019
Proportion of gross hematuria amongst
those referred for clinical workup1,200,000Pacific Edge estimate
Proportion of microhematuria amongst
those referred for clinical workup4,800,000Pacific Edge estimate
Proportion of low-risk microhematuria 340,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Proportion of intermediate-risk
microhematuria 1,960,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Proportion of high-risk microhematuria 2,500,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Annual cases of bladder cancer 180,000
Uroweb
Patients living with bladder cancer 900,000Pacific Edge estimate - 5 years of annual cases
Test opportunities 7,350,000Pacific Edge estimate
Price of Cxbladder EURO€245Pacific Edge estimate
TAM (US$billion)$2.0
SOURCES AND ASSUMPTIONS - TOTAL ADDRESSABLE MARKET (APAC)
33
REGIONSTATISTICSOURCE
APAC (EXCLUDING INDIA
AND CHINA)
Population
830,000,000
World population - Southeast Asia
Population Pyramid - Japan
Population Pyramid - Hong Kong
Incidence of hematuria16,600,000
Science Direct
Referred for clinical workup
8,300,000
Presentation from Dr Sia Daneshmand (Director of
Urologic Oncology and Clinical Research, USC) July 2019
Proportion of gross hematuria amongst
those referred for clinical workup
1,660,000
Pacific Edge estimate
Proportion of microhematuria amongst
those referred for clinical workup
6,640,000
Pacific Edge estimate
Proportion of low-risk microhematuria
470,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
AUA 2025 guidelines
Proportion of intermediate-risk
microhematuria
2,710,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
AUA 2025 guidelines
Proportion of high-risk microhematuria
3,460,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
AUA 2025 guidelines
Annual cases of bladder cancer
58,000
WHO
Hong Kong
Patients living with bladder cancer 290,000Pacific Edge estimate - 5 years of annual cases
Test opportunities 3,494,000Pacific Edge estimate
Price of Cxbladder (US$)$550Pacific Edge estimate
TAM (US$billion)$1.9
KEY CLINICAL ADVISORS AND CONSULTANTS
Associate Professor Katie Murray, DOMS, FACS
Institution: NYU Langone
Relationship: Consultant, CAB member,
Brief Bio: Published >80 articles. Deputy Editor for J Urol.
Leadership roles for SUO Young Urologic Oncology Clinical Trials
Professor Jonathan Wright, MD, MS, FACS
Institution: Fred Hutchinson Cancer Center at UW
Relationship: Consultant, CAB member, CT PI
Brief Bio: Member of ACS, SUO, AUA
Professor Wade Sexton, MD
Institution: University of South Florida & Moffitt Cancer Center
Relationship: Consultant, CAB member
Brief Bio: Published >100 articles. NCCN Bladder Cancer
Guidelines, AUA Annual Board Review Course
Professor Jay Raman, MD
Institution: Penn State and Hershey Medical Center
Relationship: Consultant, CAB member, CT PI
Brief Bio: Published >350 articles. Chair of AUA Office of Education
and Past-President of the Mid-Atlantic AUA section. Urology
Advisory Council for ACS, Hematuria Guidelines member
Associate Professor Kristen Scarpato, MD, MPH, FACS
Institution: Vanderbilt University Medical Center
Relationship: Consultant, CAB member, CT PI
Brief Bio: SUO Education Committee, AUA Core Curriculum,
Urology Practice Editorial Committee
Professor Yair Lotan, MD
Institution: UT Southwestern Medical Center
Relationship: Consultant, CAB member, IIT PI, CT PI
Brief Bio: Published >500 articles. Contributor to AUA/ASCO/ASTRO
MIBC and Hematuria Guidelines. Chair of AUA Core Curriculum. BCAN
Adboard
Professor Sam Chang, MD, MBA
Institution: Vanderbilt Cancer Center
Relationship: Consultant, CAB member
Brief Bio: Published >200 articles. Chair of AUA NMIBC Guidelines,
SUO Executive Board, ABU/AUA Examination Committee, BCAN
Adboard, AUA representative to the AJCC
Assistant Professor John Sfakianos
Institution: Icahn School of Medicine at Mount Sinai
Relationship: Consultant, CAB member
Brief Bio: Published >20 articles. Reviewer for J Urol and Urologic
Oncology
Professor Dan Barocas, MD, MPH, FACS
Institution: Vanderbilt University Medical Center
Relationship: Consultant, CAB member
Brief Bio: Published >100 articles. AUA Guidelines panel for
microscopic hematuria. Reviewer for AUA educational materials
Associate Professor, Siamak Daneshmand, MD
Institution: Keck School of Medicine at USC
Relationship: Consultant, CAB member, CT PI
Brief Bio: Published >200 articles. Editorial board of the J Urol,
Bladder Cancer Journal, Current Opinions in Urology, BCAN Adboard,
AUA/SUO Guideline Committee on NMIBC
ASCO: American Society of Clinical Oncology
ASTRO: American Society of Radiation Oncology
AUA: American Urological Association
BCAN: Bladder Cancer Advocacy Network
CAB: Clinical Advisory Board
CT PI: Clinical Trials Principal Investigator
FACS: Fellow of the American College of Surgeons
IIT PI: Investigator Initiated Trial Principal Investigator
J Urol: Journal of Urology
KOL: Key Opinion Leader
MPH: Master of Public Health
SUO: Society of Urologic Oncology
34
OUTLOOK: POSITIONED TO UNLOCK VALUE
MULTIPLE COMMERCIAL, CLINICAL AND INNOVATION CATALYSTS
LONG-TERM VALUE CREATION
RESEARCH INNOVATION
MEDIUM-TERM VALUE CREATION
CLINICAL EVIDENCE GENERATION
NEAR-TERM VALUE CREATION
COMMERCIAL CATALYSTS
•Case-by-case reimbursement for Triage
and Triage Plus under draft LCD, with first
Novitas payments received
•New LCD effective from 20 Dec 2026
•US customers adopt Triage Plus at
US$1,328/test
•Building US Commercial payer medical
policy momentum
•Evidence generation program delivers
sustained strategic value
•US commercial payer policy for Triage
and Triage Plus drives test adoption
•AUA guideline review (2027/28)
expected to expand serviceable market
•Investigator initiated trials (IITs) generate
novel evidence for new indications
•Triage Plus and Surveillance Plus deliver
better patient outcomes at higher
margin pricing for improved unit
economics
•SurveillancePlus CPT-PLA coding
submission in June 2027 and claim-by-
claim revenue from Jan 1, 2028
•Seeking US$1,800 CMS pricing for
Surveillance Plus in FY28
•Product simplification and kitted IVD
products enable de-centralized
deployment in international markets
35
INDEPENDENT DIRECTORS
SARAH PARK
ANATOLE MASFEN
BRYAN WILLIAMS
ANNA STOVE
TONY BARCLAY
SIMON FLOOD
Chairman
Simon has spent more than 25
years in the global investment
management industry having held
senior Investment and Business
Leadership roles in some of the
world’s pre-eminent investment
management firms including
Merrill Lynch Investment Managers
Lion Global Investors and AXA
Investment Managers
DR PETER MEINTJES
Chief Executive Officer
Peter is a molecular diagnostics and
genomics leader focused on
nascent market development of
disruptive innovations to drive
commercial success. Prior to joining
Pacific Edge, he was based in
Boston in a succession of diagnostic
leadership roles. Most recently he
was the Chief Commercial Officer
at Eurofins Transplant Genomics
and before that he was CEO at
Omixon
SENIOR LEADERSHIP TEAM
GRANT GIBSON DR TAMER ABOUSHWAREB DR JUSTIN HARVEY
Chief Financial Officer Chief Medical Officer Chief Technology Officer
GLEN COSTIN DARRELL MORGAN ZOE O’DONNELL
President Asia Pacific Chief Operating Officer Global Head of People & Culture
PROFESSOR PARRY GUILFORD WILLY IGLESIAS
Chief Scientific Officer Chief Digital Officer
PACIFIC EDGE BOARD AND MANAGEMENT
36
FOR MORE INFORMATION:
Dr. Peter Meintjes
Chief Executive Officer
email: peter.meintjes@pelnz.com
Grant Gibson
Chief Financial Officer
email: grant.gibson@pelnz.com
Pacific Edge
87 St David Street, PO Box 56, Dunedin, New Zealand
P +64 3 577 6733 Within NZ 0800 555 563
email: investors@pacificedge.co.nz
www.pacificedgedx.com
37
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- PHL — Promisia Healthcare Limited: ASM 2026 Presentation2026-08-27
“26 Disclaimer This presentation has been prepared by Promisia Healthcare Limited (“PHL”). The information in this presentation is of a general nature only. It is not a complete description of PHL. This presentation is not a recommendation or offer of financial products for subsc…”
- BPG — Black Pearl Group Limited: Q2 FY27 Investor Webinar2026-10-15
“BLACKPEARL GROUP | INVESTOR ANNOUNCEMENT 15 OCTOBER 2026 Q2 FY27 Investor Webinar Blackpearl Group Limited (NZX/ASX: BPG) advises that it will host an investor webinar at 12.30pm NZDT / 10.30am AEDT on Tuesday, 20 October 2026, following the release of its Q2 FY27 update.…”
- BPG — Black Pearl Group Limited: Amended FY26 Annual Report and Presentation2026-09-10
“BLACKPEARL GROUP | INVESTOR ANNOUNCEMENT 11 SEP 2026 Amended FY26 Annual Report and Investor Presentation Blackpearl Group Limited (NZX/ASX: BPG) attaches amended versions of its FY26 Annual Report and Investor Presentation, released to the market on 28 May 2026. T…”